ANGLE plc  

(Public, LON:AGL)   Watch this stock  
Find more results for Andrew Angle�
+0.35 (0.51%)
Real-time:   8:51AM GMT
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 66.54 - 68.35
52 week 63.00 - 104.50
Open 68.00
Vol / Avg. 21,449.00/129,027.00
Mkt cap 30.77M*
P/E     -
Div/yield     -
EPS -0.02*
Shares 45.24M
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Apr '14) 2014
Net profit margin -196.90% -154.56%
Operating margin -205.17% -168.54%
EBITD margin - -315.61%
Return on average assets -23.03% -18.10%
Return on average equity -21.16% -16.35%
Employees 28 -
CDP Score - -


The Surrey Research Park 3 Frederick Sanger Road
United Kingdom - Map
+44-1483-685830 (Phone)
+44-1483-685836 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


ANGLE plc (ANGLE) is a holding commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health. The Company�s principal subsidiaries are Parsortix Inc (Parsortix) and Novocellus Limited, which are commercially driven specialist medical diagnostics companies with pioneering products in cancer diagnostics and foetal health. ANGLE also owns a major investment in Geomerics Limited, a business with a computer graphics technology platform, and a specialist technology consultancy. The Company operates in four segments: Controlled investments in medical diagnostics, Non-controlled investments, Ventures and Management services. ANGLE has developed its Parsortix technology to capture circulating tumor cells (CTCs) in cancer patient blood. In December 2013, ANGLE plc sold Geomerics Limited to ARM Holdings plc.

Officers and directors

Andrew D. W. Newland Chief Executive, Executive Director
Ian F. Griffiths Finance Director, Company Secretary, Executive Director
Garth R. Selvey Non-Executive Chairman of the Board
Age: 59
Brian Howlett Non-Executive Director
David W. Quysner CBE Non-Executive Independent Director
Age: 67